This round is no longer accepting investments, but hundreds just like it are live now.

Log In

GET A PIECE OF EO2 CONCEPTS

Oxygen-Enhanced Technology for Advanced Wound Healing and Skin Support

EO2 Concepts is an advanced wound healing technology company leveraging continuous diffusion of oxygen (CDO) therapy to commercialize innovative medical modalities. The company’s primary in-market product is OxyGeni, a wearable device designed to heal wounds to complete closure while simultaneously supporting skin and soft tissue restoration, shortening recovery time, reducing pain, and minimizing the formation of scar tissue in the process.

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

$867,145.97 Raised

Log In

REASONS TO INVEST

EO2’s CDO therapy system is an enhanced wound care solution that improves patient outcomes when recovering from chronic wounds, skin injuries, or surgeries. It utilizes the continuous delivery of oxygen directly to the tissue, which has been shown to achieve faster healing, reduced pain levels, and overall improved skin health.*

EO2’s addressable market encompasses two multibillion dollar divisions. Globally, the chronic wound care sector is estimated to be worth over $20B,*while the aesthetics and cosmetic surgery industry is valued at $63.4B and expected to exhibit nearly double digit CAGR between now and 2030.*

As an industry innovator, EO2 is focused on continual product testing, research, development, and design, in collaboration with key opinion leaders and medical professionals. Our unique position in an expanding marketplace is secure through 2038, protected by numerous national and international patents, as well as additional patents pending.

*Market information provided by (source) (source) (source)

overview


Advanced Wound Care Therapy Powered By Pure Oxygen

For patients recovering from wounds (i.e. ulcers and burns), amputations, and cosmetic/restorative surgeries, oxygen is one of the most vital elements in the wound-healing process (source). Understanding this, EO2 has developed proprietary technology that allows pure, humidified oxygen to be continuously diffused directly into the tissue, thereby creating an optimal environment for skin repair and restoration. The OxyGeni is an all-inclusive system that offers oxygen generation, wound monitoring, oxygen diffusion dressings, and accessories, all in one lightweight and discrete wearable device.


The Problem & Our Solution



Making CDO Therapy Accessible To Support Wound Healing 24/7



A common obstacle to proper healing of wounds is a lack of oxygen, caused by blocked or damaged blood pathways. Oxygen via the bloodstream is what provides nourishment to the skin and dermal tissues, fueling important processes like collagen formation, cellular regeneration, antibacterial activity, and repair. When the body doesn’t have access to sufficient levels of oxygen, it becomes much harder to carry out these essential functions. However, most existing wound care options involve covering damaged skin, thereby blocking direct flow of oxygen to the tissue.


source

As a solution, EO2 has developed a system that not only restores oxygen levels, yet also enhances those levels beyond the body’s normal capacity. Using our wearable device, patients receive advanced wound care anywhere, anytime, and are able to accelerate the entire healing process. Additionally, because CDO therapy has benefits for reducing pain and inhibiting the formation of scars, the technology helps to restore quality of life. Positive outcomes from treatment with OxyGeni range from improving aesthetic appearance to preventing amputation.  

The Market & Our Traction



Building a Science-Backed Brand That’s Responsive To An Evolving Market 


Over the last several years, EO2 has been making significant progress across many verticals. In clinical trials, the company’s technology has been substantiated by multiple studies, with peer-reviewed papers published by notable national and international industry leaders. Meanwhile, on the marketing side, we’ve seen mass social media response to the performance of our products for patients, especially in the cosmetic procedures market. 



As a result of our success in these areas, EO2 has seen a robust increase in sales. Within the plastics and aesthetics market, we’ve demonstrated triple-digit YOY growth and in Canada, the company has moved from unpaid trials to payment models in six provinces. By creating products designed to accommodate today’s telehealth models, we are enabling patients to be more involved in their own care through mobile app design, automated product delivery, and AI-driven communication. 



Although EO2 Concepts initially developed solutions for the chronic wound care market, the company has exciting opportunities to expand into other markets based on the science of oxygen therapy’s efficacy and the feedback of medical users. Our newest and fastest-growing market is in aesthetic and reconstructive surgery, as the technology can be used to facilitate healing following face lifts, breast reductions, laser facials, and cosmetic injectables. 


Why Invest



Invest in Proven Technology That Helps People Heal



Chronic wounds affect millions of patients each year and the costs to our healthcare system for diabetic foot complications alone are comparable to all cancers combined (source). Complications from a wound can last months or years, sometimes resulting in amputations, and severely impacting quality of life for patients. Having developed a system that can improve recovery outcomes, in a more accessible and affordable format, EO2’s vision is to bring our technology to the medical community and become the standard of care across multiple segments. Be a part of our success story by investing on Start Engine!



ABOUT

HEADQUARTERS
12500 Network Blvd Ste 310
San Antonio, TX 78249
WEBSITE
View Site

EO2 Concepts is an advanced wound healing technology company leveraging continuous diffusion of oxygen (CDO) therapy to commercialize innovative medical modalities. The company’s primary in-market product is OxyGeni, a wearable device designed to heal wounds to complete closure while simultaneously supporting skin and soft tissue restoration, shortening recovery time, reducing pain, and minimizing the formation of scar tissue in the process.

TEAM

Mark Niederauer

Mark Niederauer

President, CEO, Board Member

Dr. Niederauer has served as the Company’s Chief Technology Advisor since June of 2008, has served as the Chief Technology and Operating Officer since January of 2010 and became the President and CEO in August of 2021. He has more than 25 years of experience in commercialization, engineering, product development and manufacturing of pharmaceuticals medical devices, including regulatory and quality compliance. Dr. Niederauer has worked for Bayer Chemikalien in Leverkusen, Germany, Hoechst Celanese in Corpus Christi, TX, and for OsteoBiologics, Inc. (OBI) in San Antonio, TX, which was the acquired by Smith & Nephew Endoscopy. Dr. Niederauer earned a PhD in Biochemical Engineering, with a focus in Genetics, from Iowa State University. He is also a Fulbright Scholar, earning the equivalent of a Master of Science degree from environmental engineering work at the Universität Stuttgart in Germany. Dr. Niederauer has co-authored numerous articles and presentations and is a co-inventor on multiple patents.

Ken Melani, MD

Ken Melani, MD

Board member

Dr. Melani is currently the owner of KRM Group LLC, a healthcare consulting firm, and managing director of Velocity Fund Partners LLC, a life sciences venture capital fund. He started his career as a practicing Internist where he founded and later became Chairman and CEO of a physician-hospital organization called West Penn Cares. Over the next twenty-five years he served in a variety of executive leadership roles at Highmark Inc, culminating as the President and CEO from 2003-2012. He was credited with growing Highmark into one of the leading healthcare companies in the United States and personally regarded as one of the top healthcare executives in the country. Dr. Melani received his BA from Washington and Jefferson College, where he graduated Summa Cum Laude, and went on to receive a Doctorate of Medicine from The Wake Forest University School of Medicine.

Tony Gallardo

Tony Gallardo

Chief Financial Officer & Secretary

Tony is a Certified Public Accountant with over years of financial and operational experience. He has overall responsibility for business financial operations including treasury, budgeting, forecasting, accounting management and human resources. Tonyhas worked as COO and CFO for entrepreneurial companies in home health care and mental health. With over years of experience Tony is adept at improving processes,including financial reporting, cash flow, internal controls and compliance with contract and regulatory requirements.As a financial leader Tony has extensive experience with budgeting and forecasting. He has guided operational teams to successfully prepare and exceed budgets. Additionally,over his career he has successfully guided the accounting team to set up the internal controls and processes for high growth companies.Tony earned his Bachelors degree in accounting from the University of Texas at SanAntonio. 

Donna Hunt

Donna Hunt

Business Manager and Assistant Secretary

Donna has over 25 years of financial and operational experience in various industries, including medical devices, finance, banking and construction. Donna manages several components of EO2’s business, including accounting, human resources, logistics,document control and facility management. Prior to joining EO2, she worked for a startup medical device company, Bluegrass Vascular Technologies, as the Business Manager until they were recently acquired. Her prior work experience was primarily in banking in various financial and executive support roles for Wells Fargo and Frost Bank.

Dave Kazynski

Dave Kazynski

Exec. VP of Sales and Marketing, Board Member

Mr. Kazynski is the President of VGM’s HOMELINK business which is a insurance network contractor for a wide range of various healthcare services for members of VGM’s independent Durable Medical Equipment suppliers. HOMELINK has about 110 different managed care contracts. He served many years as a CFO and COO to a number of proprietary hospitals in IA and MO including a hospital sold to Tenet. Mr. Kazynski has been a member on the Center for Medicare Services DME Program Advisory and Oversight Committee (PAOC) and functioned as the hospital liaison for local Managed Care Plans. Mr. Kazynski graduated from the University of Northern Iowa in 1979 with a B.A. in Psychology, and then earned an M.B.A. in Finance in 1981.

Peter Smith

Peter Smith

Chairman of the Board of Directors

Mr Smith served as the Chief Operating Officer of Baxter's Japanese Subsidiary located in Tokyo and later was the President of Baxter's Caremark Division. He founded and led CorSolutions, a disease management company. Subsequently, he also founded and led Medmark, a specialty pharmaceutical distribution business. He currently sits on the Board of four other privately held healthcare companies. Mr Smith received his AB from Princeton University and his MBA from the University of Chicago.

Jim DeYoung

Jim DeYoung

Board Member

Mr. DeYoung is founder and a principal of Winston Partners Incorporated, which provides strategic corporate advisory and investor relations services to private and public companies. In addition, Mr. DeYoung is a member of the management of DW Investments, LLC. Mr. DeYoung formerly was a general partner of Resource Ventures L.P. He was responsible for several of the fund’s investments. He served at Baxter International, Inc. in marketing, investor relations, public relations and corporate financial management functions. He is a Trustee of Rush University Medical Center and serves on the Executive, Investment and Information Technology Committees of the Board. Mr. De Young serves on a number of boards in the Chicago area. Mr. DeYoung is a graduate of Washington and Lee University (B.A.) and received his J.D. degree from Northwestern University School of Law.

James P. Daley

James P. Daley

Director of Operations

Mr. Daley has over 45 years’ experience in electrical and mechanical engineering, manufacturing and product development in the fields of medical devices and aerospace. He oversees the research, design, manufacturing, packaging and testing of products. Mr. Daley also manages all plant operations, including shipping & receiving and facility maintenance. Mr. Daley is a co-inventor on multiple patents.

Cyndi Gilliam, BSN, RN, FACCWS

Cyndi Gilliam, BSN, RN, FACCWS

Director of Clinical Affairs

Mrs. Gilliam is the Director of Clinical Affairs for EO2. She has worked as an industry Clinical Specialist for the last 10 years, including experience at Kinetic Concepts Inc. Her experience and expertise as a wound care RN has been instrumental in the relationships and educational programs she has built throughout the years. She has excellent contacts across the country within wound care, colorectal surgery, orthopedic, and other specialties. Her passion is integrating her business knowledge with her clinical knowledge to achieve the greatest outcomes for both her patients and clinicians, while achieving success for the company. She is excited to bring her knowledge and skills to help bring EO2 to the forefront of wound care as a standard of care therapy system.

Kate Biasiolli

Kate Biasiolli

Marketing Manager

Mrs. Biasiolli currently holds position as both regional account manager in Texas as well as marketing manager. She has vast experience with in the wound care industry spanning over 15 years. During her tenure at the largest negative pressure wound therapy company, Kinetic Concepts Inc, Mrs. Biasiolli planned, developed and executed customer training throughout the globe while managing her team and million dollar budget. Her honors degree in biology combined with a certificate in adult education provides her a strong background to grasp complex processes and simplify into easy to understand, relatable concepts.

Joseph Monosmith

Joseph Monosmith

Quality Assurance Manager

Mr. Monosmith is the Quality Assurance Manager for EO2, with 13 years of experience in the Medical Device field. He has experience in manufacturing, assembly, shipping/receiving, quality control and quality assurance. In the medical device space, he previously worked in manufacturing and quality for the Endoscopy Division of Smith & Nephew. He is dedicated to, and strongly believes in, the innovation that EO2 brings to wound care, as well as, the positive impact to the quality of life for the patient population.

TERMS

EO2 Concepts
Overview
PRICE PER SHARE
$1.59
DEADLINE
Aug 30, 2023
VALUATION
$78.44M
FUNDING GOAL
$15k - $1.23M
Breakdown
MIN INVESTMENT
$298.92
MAX INVESTMENT
$1,234,997.52
MIN NUMBER OF SHARES OFFERED
9,433
MAX NUMBER OF SHARES OFFERED
776,728
OFFERING TYPE
Equity
ASSET TYPE
Preferred Stock
SHARES OFFERED
Series A Preferred Stock

Maximum Number of Shares Offered subject to adjustment for bonus shares

Most Recent Fiscal Year-End

Prior Fiscal Year-End

Total Assets

$3,568,756

$1,719,463

Cash & Cash Equivalents

$606,116

$72,823

Accounts Receivable

$1,006,778

$1,024,322

Short-Term Debt

$2,090,703

$1,386,548

Long-Term Debt

$7,799,257

$4,446,595

Revenue & Sales

$2,983,348

$1,544,623

Costs of Goods Sold

$884,839

$640,373

Taxes Paid

$0

$0

Net Income

-$2,738,366

-$2,517,980

A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.

*Maximum number of shares offered subject to adjustment for bonus shares. See Bonus info below.

Time Based Perks

o First 72 hours – 10% Super Early Bird Bonus

o First week (days 4-7) – 8% Very Early Bird Bonus

o First 3 weeks (week 2 & 3) - 5% Early Bird Bonus

Amount Based Perks

o $600+ – 3% bonus shares , Member, Contributing to enabling advanced healing with oxygen.

o $1,500+ – 5% bonus shares, Leader, Leading the way in oxygen healing solutions.

o $5,000+ – 8% bonus shares, Innovator, Bringing next generation solutions to oxygen delivery and patient monitoring.

o $15,000+ – 10% bonus shares, Visionary, Ensuring the long-term growth and innovation in oxygen solutions for health care. 

Loyalty Bonus - 10% Bonus Shares for Friends and Family 

*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

Electrochemical Oxygen Concepts, Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Series A Non-Voting Preferred Stock at $1.59/ share, you will receive 110 shares of Series A Non-Voting Preferred Stock, meaning you'll own 110 shares for $159. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investor's eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and the time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus and an the Loyalty bonus in addition to the aforementioned bonus.

Irregular Use of Proceeds

The Company will not incur irregular use of proceeds.

PRESS

Article Image
Meta-analysis Published

Efficacy of Topical Wound Oxygen Therapy in Healing Chronic Diabetic Foot Ulcers: Systematic Review and Meta-Analysis

Article Image
Fully Blinded Placebo Study

Continuous diffusion of oxygen improves diabetic foot ulcer healing when compared with a placebo control: a randomised, double-blind, multicentre study

Article Image
VIDEO: EO2 on PBS SciTech Now

Featured on PBS SciTech Now on July 14th, 2017, Dr. Mark Niederauer, explains the EO2 Device and CDO Therapy.

ALL UPDATES

Owners bonus
Stack Owner's Bonus & Rewards!

Members get an extra 10% shares in addition to rewards below!

REWARDS

Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into EO2 Concepts.

JOIN THE DISCUSSION

0/2500

BS
Brian Sims

a month ago

I've already invested and looking to make an additional investment. Why wouldn't CDO be used for all surgeries? Has it been tried for open heart surgery patients that have great scarring? I've been watching and reading about the benefits of CDO and it all looks extremely positive. I can't find anything negative about this. Usually start ups looking for acquisition or IPO. If the latter, any time line?

1

0

‌
‌
‌
‌

‌
‌
‌
‌

‌
‌
‌
‌

PK
Patrick Kennedy

a month ago

Gentlemen, Is this really the final raise and if not what will be the valuation next time.?

1

0

‌
‌
‌
‌

‌
‌
‌
‌

‌
‌
‌
‌

RK
Richard Koch

3 months ago

I viewed Dr. Armstrong's video. It leaves me with obvious questions about insurance coverage. Who's working the issue of having this therapy covered by insurance? Is a decision close? Have insurance honchos turned their noses up, or is this following the [notionally] logical track to likely approval?

1

0

‌
‌
‌
‌

‌
‌
‌
‌

‌
‌
‌
‌

WC
W Kim Colich

4 months ago

Hi Mark, I'm wondering... Do you see potential for your product in the world of sports, i.e. helping athletes perform their absolute best with boosts of oxygen to their tissues? Thanks. Blessings

1

0

‌
‌
‌
‌

‌
‌
‌
‌

‌
‌
‌
‌

CL
Christopher Lill

4 months ago

Hello, I would like to know more about your patents ie how many you have and how many pending? Th×

2

0

‌
‌
‌
‌

‌
‌
‌
‌

‌
‌
‌
‌

SH
Stephen Hart

5 months ago

Is this system available now?

4

0

‌
‌
‌
‌

‌
‌
‌
‌

‌
‌
‌
‌

TD
Terry Dew

5 months ago

What differentiates you from other similar units on the market?

1

0

‌
‌
‌
‌

‌
‌
‌
‌

‌
‌
‌
‌

MM
Michael Myers

5 months ago

Exciting technology, I work in the DME industry and have dealt w/NPWT which is a pain both for the patient and the DME, would be interested in considering this as a new product line, especially w/cash options to plastic/reconstructive surgery being a potential customer.

1

0

‌
‌
‌
‌

‌
‌
‌
‌

‌
‌
‌
‌

JR
Joseph Russo

6 months ago

This really interested me. As my mother in law had her feet slowly taken off but by bit because she could not heal the area. This would have save her life because she would not have suken into a deep depression that she never came out of. I believe this will save more then time and money in medical costs but the mental health issues related to wounds that don’t heal.

1

0

‌
‌
‌
‌

‌
‌
‌
‌

‌
‌
‌
‌

RJ
Ronnie Jaikaran

6 months ago

Hello. Is there any tax documents that I need from you for my 2022 filing? Start-up investing is all new to me.

1

0

‌
‌
‌
‌

‌
‌
‌
‌

‌
‌
‌
‌

HOW INVESTING WORKS

Cancel anytime before 48 hours before a rolling close or the offering end date.

WHY STARTENGINE?

REWARDS

We want you to succeed and get the most out of your money by offering rewards and memberships!

SECURE

Your info is your info. We take pride in keeping it that way!

DIVERSE INVESTMENTS

Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.

RAISED
$867,145.97
INVESTORS
273
MIN INVEST
$298.92
VALUATION
$78.44M

Get To Know Us

Our Team

Careers

Blog

Let's Work Together

Raise Capital

Refer a Founder, earn $10k

Success Stories

Partnerships

Need Help

Contact Us

Help Center

Terms of Use

Privacy Policy

Disclaimer

Annual Reports

Form CRS

Terms of Use

Privacy Policy

Disclaimer

Annual Reports

Form CRS

Important Message

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.

www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.
Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRASIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.

Investment opportunities posted and accessible through the site are of three types:

1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.
By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.

Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

California Investors Only – Do Not Sell My Personal Information

(800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.

StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.

StartEngine Marketplace

The availability of company information does not indicate that the company has endorsed, supports, or otherwise participates with StartEngine.

None of the information displayed on or downloadable from www.startengine.com (the 'Website') represents a recommendation, offer, or solicitation of an offer to buy or sell any security. It also does not constitute an offer to provide investment advice or service. StartEngine does not (1) make any recommendations or otherwise advise on the merits or advisability of a particular investment or transaction, or (2) assist in the determination of fair value of any security or investment, or (3) provide legal, tax, or transactional advisory services.

All investment opportunities are based on indicated interest from sellers and will need to be confirmed.

Investing in private company securities is not suitable for all investors. An investment in private company securities is highly speculative and involves a high degree of risk. It should only be considered a long-term investment. You must be prepared to withstand a total loss of your investment. Private company securities are also highly illiquid, and there is no guarantee that a market will develop for such securities. Each investment also carries its own specific risks, and you should complete your own independent due diligence regarding the investment. This includes obtaining additional information about the company, opinions, financial projections, and legal or other investment advice. Accordingly, investing in private company securities is appropriate only for those investors who can tolerate a high degree of risk and do not require a liquid investment.

StartEngine Marketplace (“SE Marketplace”) is a website operated by StartEngine Primary, LLC (“SE Primary”), a broker-dealer that is registered with the SEC and a member of FINRA and the SIPC. StartEngine Bulletin Board ("SE BB") is a bulletin board platform that advertises interest in shares of private companies that previously executed Reg CF or Reg A offerings. SE BB enables shareholders to communicate interest in potential sales of shares in private companies and investors to discover, review, and potentially invest in private companies. As a bulletin board platform, SE BB provides a venue for investors to access information about private company offerings and connect with potential sellers. SE BB is distinct and separate from StartEngine Secondary (“SE Secondary”), which is an SEC-registered Alternative Trading System (ATS) operated by SE Primary. SE Secondary facilitates the trading of securities by matching orders between buyers and sellers and facilitating executions of trades on the platform. While a security may be displayed on the bulletin board, these securities will be subject to certain restrictions which may prevent the ability to buy and sell these securities in a timely manner, if at all. Even if a security is qualified to be displayed on the bulletin board, there is no guarantee an active trading market for the securities will ever develop, or if developed, be maintained. You should assume that you may not be able to liquidate your investment for some time or be able to pledge these shares as collateral.